ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco

Core Insights - ZyVersa Therapeutics, Inc. is advancing a pipeline of first-in-class drug candidates targeting inflammatory and renal diseases with high unmet medical needs [1][5] - The company is developing two main drug candidates: Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications and Cholesterol Efflux Mediator VAR 200 for diabetic kidney disease [1][2][5] - ZyVersa is participating in the JPM's 43rd Annual Healthcare Conference 2025 to discuss its technology and pipeline assets [3][4] Drug Candidates - Inflammasome ASC Inhibitor IC 100 aims to reduce disease-causing inflammation, with a lead indication of obesity and related metabolic complications [1][5] - Cholesterol Efflux Mediator VAR 200 is designed to facilitate the removal of renal lipids and cholesterol, with a phase 2a clinical trial expected to start in Q1-2025 for diabetic kidney disease [2][5] Market Potential - The total accessible market for ZyVersa's therapeutic areas exceeds $100 billion, indicating significant growth opportunities [5]